• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Barnes Alane P bought $27,650 worth of shares (5,000 units at $5.53), increasing direct ownership by 2% to 300,762 units (SEC Form 4)

    5/15/24 7:11:17 AM ET
    $BCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $BCRX alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Barnes Alane P

    (Last) (First) (Middle)
    4505 EMPEROR BLVD.
    SUITE 200

    (Street)
    DURHAM NC 27703

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    BIOCRYST PHARMACEUTICALS INC [ BCRX ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Legal Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    05/13/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 05/13/2024 P 5,000 A $5.53(1) 300,762 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. The price in column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $5.36 to $5.64. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
    /s/ Alane P. Barnes 05/15/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $BCRX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BCRX

    DatePrice TargetRatingAnalyst
    10/15/2025$30.00Buy
    TD Cowen
    10/1/2025$8.00Outperform → In-line
    Evercore ISI
    4/29/2025$20.00Overweight
    Cantor Fitzgerald
    2/25/2025$15.00Outperform
    Wedbush
    11/20/2023$10.00Overweight
    JP Morgan
    9/18/2023$9.00 → $10.00Sector Perform → Outperform
    RBC Capital Mkts
    8/4/2023$11.00Hold → Buy
    Jefferies
    7/13/2023$10.00Neutral → Buy
    BofA Securities
    More analyst ratings

    $BCRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BioCryst to Present New Pediatric HAE Data at the American College of Allergy, Asthma & Immunology 2025 Annual Scientific Meeting

    RESEARCH TRIANGLE PARK, N.C., Oct. 23, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present four abstracts at the Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) taking place in Orlando, Fla., from November 6-10, 2025. The data will include results from a second interim analysis of the APeX-P trial evaluating long-term prophylaxis with an oral granule formulation of once-daily ORLADEYO® (berotralstat) in pediatric patients with hereditary angioedema (HAE) aged 2 to <12 years as well as findings on the psychosocial impact of HAE on young patients and their caregivers. BioCryst poster p

    10/23/25 7:00:14 AM ET
    $BCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BioCryst to Report Third Quarter 2025 Financial Results on November 3

    RESEARCH TRIANGLE PARK, N.C., Oct. 20, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its third quarter 2025 financial results on Monday, November 3, 2025. BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update. The live call may be accessed by dialing 1-844-481-2942 for domestic callers and 1-412-317-1866 for international callers. A live webcast and replay of the call will be available online in the investors section of the company website at www.biocryst.com. About BioCryst Pharmaceuticals BioCryst Pharmaceuticals is a glob

    10/20/25 7:00:00 AM ET
    $BCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile

    – Deal to add navenibart, a late-stage and long-acting plasma kallikrein inhibitor, in Phase 3 clinical development, to BioCryst's HAE portfolio – – Solidifies double digit growth trajectory for HAE portfolio over the next decade – – BioCryst expects to remain profitable (non-GAAP) and cash flow positive post-transaction – – Implied aggregate equity-value of approximately $920 million and implied enterprise value of approximately $700 million – – BioCryst to host conference call today at 8:00 a.m. ET – RESEARCH TRIANGLE PARK, N.C. and BOSTON, Oct. 14, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) and Astria Therapeutics, Inc. (NASDAQ:ATXS) today announced that

    10/14/25 7:00:39 AM ET
    $ATXS
    $BCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $BCRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    TD Cowen resumed coverage on BioCryst Pharma with a new price target

    TD Cowen resumed coverage of BioCryst Pharma with a rating of Buy and set a new price target of $30.00

    10/15/25 8:23:22 AM ET
    $BCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BioCryst Pharma downgraded by Evercore ISI with a new price target

    Evercore ISI downgraded BioCryst Pharma from Outperform to In-line and set a new price target of $8.00

    10/1/25 8:12:55 AM ET
    $BCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cantor Fitzgerald initiated coverage on BioCryst Pharma with a new price target

    Cantor Fitzgerald initiated coverage of BioCryst Pharma with a rating of Overweight and set a new price target of $20.00

    4/29/25 8:10:45 AM ET
    $BCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BCRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Levin Alan G bought $49,996 worth of shares (7,861 units at $6.36), increasing direct ownership by 21% to 44,951 units (SEC Form 4)

    4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)

    5/31/24 4:25:31 PM ET
    $BCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Aselage Steve bought $16,000 worth of shares (2,500 units at $6.40) (SEC Form 4)

    4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)

    5/29/24 4:16:35 PM ET
    $BCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Hutson Nancy J bought $31,900 worth of shares (5,000 units at $6.38), increasing direct ownership by 6% to 86,818 units (SEC Form 4)

    4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)

    5/22/24 7:24:51 AM ET
    $BCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BCRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mckee Amy E was granted 676 shares, increasing direct ownership by 2% to 41,007 units (SEC Form 4)

    4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)

    9/3/25 4:30:01 PM ET
    $BCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Frank Steven was granted 1,353 shares, increasing direct ownership by 9% to 16,052 units (SEC Form 4)

    4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)

    9/3/25 4:07:34 PM ET
    $BCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Milano Vincent was granted 676 shares, increasing direct ownership by 0.75% to 90,436 units (SEC Form 4)

    4 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Issuer)

    9/3/25 4:04:50 PM ET
    $BCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BCRX
    SEC Filings

    View All

    BioCryst Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Leadership Update, Other Events, Financial Statements and Exhibits

    8-K - BIOCRYST PHARMACEUTICALS INC (0000882796) (Filer)

    10/14/25 7:10:18 AM ET
    $BCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BioCryst Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

    8-K - BIOCRYST PHARMACEUTICALS INC (0000882796) (Filer)

    10/1/25 8:03:50 AM ET
    $BCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form S-8 filed by BioCryst Pharmaceuticals Inc.

    S-8 - BIOCRYST PHARMACEUTICALS INC (0000882796) (Filer)

    8/12/25 4:09:15 PM ET
    $BCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BCRX
    Leadership Updates

    Live Leadership Updates

    View All

    BioCryst to Highlight Patient-focused Research at the 2025 US HAEA National Summit

    RESEARCH TRIANGLE PARK, N.C., July 09, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present new findings from patient-focused research highlighting the burden of current treatments for HAE on pediatric patients under the age of 12 and their caregivers and perspectives on the importance of HAE treatments. The findings will be presented in posters at the 2025 US HAEA National Summit in Baltimore, which is taking place July 10-13, 2025. "For more than a decade, we have been honored to join the HAE patient community at the US HAEA National Summit. It is an opportunity for us to hear directly from them on their hopes and dreams

    7/9/25 7:00:00 AM ET
    $BCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BioCryst Appoints Babar Ghias Chief Financial Officer and Head of Corporate Development

    RESEARCH TRIANGLE PARK, N.C., July 07, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced the appointment of Babar Ghias as chief financial officer (CFO) and head of corporate development. Mr. Ghias joins BioCryst from AvenCell Therapeutics, a clinical-stage CAR-T company focused on hematologic malignancies, where he served as CFO since 2022. "Babar brings extensive deal making and operational experience in addition to his previous roles as a CFO at rare disease companies. The addition of these skills and expertise to the leadership team are exactly what we need at this time as we look to deploy capital and accelerate our path to sustainable growth and

    7/7/25 7:00:22 AM ET
    $BCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BioCryst Appoints Steve Frank to Board of Directors

    RESEARCH TRIANGLE PARK, N.C., May 01, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the company has appointed healthcare investment banking leader Steve Frank to its board of directors. Mr. Frank serves as chairman of global healthcare investment banking at J.P. Morgan. He was previously global group head of worldwide healthcare investment banking at Bear Stearns before it was acquired by J.P. Morgan in 2008. Mr. Frank is a trusted corporate advisor, supporting countless transactions including pharmaceutical, biotechnology, medical device and healthcare services firms. A standout institutional investor before becoming a banker, Mr. Frank direct

    5/1/25 7:00:20 AM ET
    $BCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BCRX
    Financials

    Live finance-specific insights

    View All

    BioCryst to Report Third Quarter 2025 Financial Results on November 3

    RESEARCH TRIANGLE PARK, N.C., Oct. 20, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its third quarter 2025 financial results on Monday, November 3, 2025. BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update. The live call may be accessed by dialing 1-844-481-2942 for domestic callers and 1-412-317-1866 for international callers. A live webcast and replay of the call will be available online in the investors section of the company website at www.biocryst.com. About BioCryst Pharmaceuticals BioCryst Pharmaceuticals is a glob

    10/20/25 7:00:00 AM ET
    $BCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile

    – Deal to add navenibart, a late-stage and long-acting plasma kallikrein inhibitor, in Phase 3 clinical development, to BioCryst's HAE portfolio – – Solidifies double digit growth trajectory for HAE portfolio over the next decade – – BioCryst expects to remain profitable (non-GAAP) and cash flow positive post-transaction – – Implied aggregate equity-value of approximately $920 million and implied enterprise value of approximately $700 million – – BioCryst to host conference call today at 8:00 a.m. ET – RESEARCH TRIANGLE PARK, N.C. and BOSTON, Oct. 14, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) and Astria Therapeutics, Inc. (NASDAQ:ATXS) today announced that

    10/14/25 7:00:39 AM ET
    $ATXS
    $BCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile

    – Deal to add navenibart, a late-stage and long-acting plasma kallikrein inhibitor, in Phase 3 clinical development, to BioCryst's HAE portfolio – – Solidifies double digit growth trajectory for HAE portfolio over the next decade – – BioCryst expects to remain profitable (non-GAAP) and cash flow positive post-transaction – – Implied aggregate equity-value of approximately $920 million and implied enterprise value of approximately $700 million – – BioCryst to host conference call today at 8:00 a.m. ET – BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) and Astria Therapeutics, Inc. (NASDAQ:ATXS) today announced that the companies have entered into a definitive agreement under which BioC

    10/14/25 7:00:00 AM ET
    $ATXS
    $BCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $BCRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by BioCryst Pharmaceuticals Inc.

    SC 13G/A - BIOCRYST PHARMACEUTICALS INC (0000882796) (Subject)

    11/7/24 10:52:17 AM ET
    $BCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by BioCryst Pharmaceuticals Inc.

    SC 13G/A - BIOCRYST PHARMACEUTICALS INC (0000882796) (Subject)

    11/7/24 10:25:46 AM ET
    $BCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by BioCryst Pharmaceuticals Inc.

    SC 13G/A - BIOCRYST PHARMACEUTICALS INC (0000882796) (Subject)

    11/4/24 11:18:36 AM ET
    $BCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care